• Progyny, Inc. Announces First Quarter 2023 Results

    Source: Nasdaq GlobeNewswire / 08 May 2023 16:03:55   America/New_York

    Reports Record Quarterly Revenue of $258.4 Million, Reflecting 50% Growth Over the Prior Year Period
    Raises Full Year Revenue and Earnings Guidance
    Strong Demand Continues for Family Building Solutions as Affirmed by Healthy Utilization, Early Sales Activity and New Partnerships

    NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a leading benefits management company specializing in fertility and family building benefits solutions, today announced its financial results for the three-month period ended March 31, 2023 (“the first quarter of 2023”) as compared to the three-month period ended March 31, 2022 (“the first quarter of 2022” or “the prior year period”).

    “We're pleased with our strong start to 2023, as the ongoing healthy demand for fertility and family building care helped us achieve our highest-ever quarterly revenue, gross profit and Adjusted EBITDA, while our continued focus on cash flow from operations has allowed us to generate our highest-ever first quarter cash flow for that metric,” said Pete Anevski, Chief Executive Officer of Progyny.  “A recent report from the World Health Organization has revealed that the prevalence of infertility - which has long been recognized as a disease - continues to increase.  Access to effective treatment for any disease is essential, and we believe fertility care should likewise be an essential benefit that's available to everyone, given the profound impact it has on both employers and their employees.

    “With that critical dynamic as a backdrop, we believe that the 5.4 million covered lives we manage today represent just a fraction of our market opportunity.  Although our selling season for 2024 launches is at its earliest stages, we are pleased that our sales and pipeline activity is favorable when compared to the record level of activity that we had a year ago.  In addition, we've already had a healthy number of early commitments as well.  We believe this positive activity, as well as our recently announced strategic relationships with Evernorth and Children's Hospital Association, further validates both the strong demand in the market, as well as our leading position as the provider of choice for fertility and family building solutions.”

    “Our first quarter gross profit increased 78% and Adjusted EBITDA nearly doubled when compared to the prior year period, reflecting the impact of our strong revenue growth, as well as the efficiencies that we continue to realize throughout our cost structure, even as we rapidly scale the business,” said Mark Livingston, Progyny’s Chief Financial Officer.

    First Quarter 2023 Highlights:

    (unaudited; in thousands, except per share amounts)1Q 2023
    		  1Q 2022
    		 
    Revenue$258,394  $172,217 
        
    Gross Profit$58,640  $32,949 
    Gross Margin 22.7%  19.1%
    Net Income$17,678  $4,971 
        
    Net Income per Diluted Share1 $0.18  $0.05 
        
    Adjusted EBITDA2$46,360  $24,806 
    Adjusted EBITDA Margin2 17.9%  14.4%

    1 Net income per diluted share reflects weighted-average shares outstanding as adjusted for potential dilutive securities, including options, restricted stock units, warrants to purchase common stock, and shares issuable under the employee stock purchase plan.
    2 Adjusted EBITDA and Adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with, U.S. generally accepted accounting principles ("GAAP"). Please see Annex A of this press release for a reconciliation of Adjusted EBITDA to net income, the most directly comparable financial measure stated in accordance with GAAP for each of the periods presented. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue.

    Financial Highlights

    Revenue was $258.4 million, a 50% increase as compared to the $172.2 million reported in the first quarter of 2022, primarily as a result of the increase in our number of clients and covered lives.

    • Fertility benefit services revenue was $157.1 million, a 42% increase from the $110.9 million reported in the first quarter of 2022.
    • Pharmacy benefit services revenue was $101.2 million, a 65% increase as compared to the $61.3 million reported in the first quarter of 2022.

    Gross profit was $58.6 million, an increase of 78% from the $32.9 million reported in the first quarter of 2022, primarily due to the higher revenue. Gross margin was 22.7%, an increase of 360 basis points from the 19.1% reported in the prior year period, primarily due to ongoing efficiencies realized in the delivery of our care management services.

    Net income was $17.7 million, or $0.18 income per diluted share, an increase of 256% as compared to the $5.0 million, or $0.05 income per diluted share, reported in the first quarter of 2022. The higher net income was due primarily to the higher gross profit and operating efficiencies realized on our higher revenues, which was partially offset by an increase in non-cash stock-based compensation expense.

    Adjusted EBITDA was $46.4 million, an increase of 87% as compared to the $24.8 million reported in the first quarter of 2022, reflecting the higher gross profit and operating efficiencies realized on our higher revenues. Adjusted EBITDA margin was 17.9%, an increase of 350 basis points from the 14.4% Adjusted EBITDA margin in the first quarter of 2022. Please refer to Annex A for a reconciliation of Adjusted EBITDA to net income.

    Cash Flow
    Net cash generated by operating activities in the first quarter of 2023 was $21.0 million, compared to a cash use of $11.3 million in the prior year period. The higher cash flow as compared to the prior year period was primarily due to higher profitability as well as timing items.

    Balance Sheet and Financial Position
    As of March 31, 2023, the Company had total working capital of approximately $320.2 million and no debt. This included cash and cash equivalents and marketable securities of $207.9 million, an increase of $18.6 million from the balances as of December 31, 2022.

    Key Metrics

    The Company had 379 clients as of March 31, 2023, as compared to 264 clients as of March 31, 2022.

     Three Months Ended March 31,
     2023 2022 
    ART Cycles*13,171 8,924 
    Utilization – All Members**0.54%0.51%
    Utilization – Female Only**0.48%0.45%
    Average Members5,335,000 3,927,000 

    * Represents the number of ART cycles performed, including IVF with a fresh embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers, and egg freezing.
    ** Represents the member utilization rate for all services, including, but not limited to, ART cycles, initial consultations, IUIs, and genetic testing. The utilization rate for all members includes all unique members (female and male) who utilize the benefit during that period, while the utilization rate for female only includes only unique females who utilize the benefit during that period. For purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period. Individual periods cannot be combined as member treatments may span multiple periods.

    Financial Outlook
    “In light of our strong results in the first quarter, as well as our current expectations for member utilization, we are raising our guidance for the year,” said Mr. Anevski.

    The Company is providing the following financial guidance for the full year ending December 31, 2023 and the three-month period ending June 30, 2023:

    • Full Year 2023 Outlook:
      • Revenue is now projected to be $1,040 million to $1,065 million, reflecting growth of 32% to 35%
      • Net income is projected to be $43.6 million to $49.0 million, or $0.42 to $0.48 per diluted share, on the basis of approximately 103 million assumed weighted-average fully diluted-shares outstanding
      • Adjusted EBITDA1 is projected to be $176.5 million to $184.0 million
    • Second Quarter of 2023 Outlook:
      • Revenue is projected to be $260.0 million to $265.0 million, reflecting growth of 33% to 36%
      • Net income is projected to be $9.3 million to $10.4 million, or $0.09 to $0.10 per diluted share, on the basis of approximately 102 million assumed weighted-average fully diluted-shares outstanding
      • Adjusted EBITDA1 is projected to be $44.0 million to $45.5 million

    1 Adjusted EBITDA is a financial measure that is not required by, or presented in accordance with, GAAP. Please see Annex A of this press release for a reconciliation of forward-looking Adjusted EBITDA to forward-looking net income, the most directly comparable financial measure stated in accordance with GAAP for the period presented.

    Conference Call Information
    Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) today, May 8, 2023, to discuss its financial results. Interested participants from the United States may join by calling 1.866.825.7331 and using conference ID 265484. Participants from international locations may join by calling 1.973.413.6106 and using the same conference ID. A replay of the call will be available until May 15, 2023 at 11:59 P.M. Eastern Time by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and entering passcode 265484. A live audio webcast of the call and subsequent replay will also be available through the Events & Presentations section of the Company’s Investor Relations website at investors.progyny.com. 

    About Progyny
    Progyny (Nasdaq: PGNY) is a leading fertility benefits management company. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive solution can simultaneously benefit employers, patients, and physicians.  

    Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation’s leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so. 

    Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Financial Times, INC. 5000, and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com. 

    Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our financial outlook for the second quarter and full year 2023; the demand for our solutions; our expectations for our selling season for 2024 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our expected utilization rates and mix; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues, ” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.

    Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the level or the mix of utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the medical landscape, regulations, client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; our ability to maintain our Company culture; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain or any disruption of our pharmacy distribution network or their supply chain; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to potential sales to government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, partnerships, or alliances; federal tax reform and changes to our effective tax rate; the imposition of state and local taxes; our ability to utilize a significant portion of our net operating loss or research tax credit carryforwards; our ability to maintain effective internal control over financial reporting; our ability to adapt and respond to the changing SEC expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and subsequent reports that we file with the SEC which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov. 

    Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.

    Non-GAAP Financial Measures
    In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release and the accompanying tables include the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted EBITDA margin on incremental revenue.

    Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EBITDA margin on incremental revenue are supplemental financial measures that are not required by, or presented in accordance with, GAAP. We believe that these non-GAAP measures, when taken together with our GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EBITDA margin on incremental revenue are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.

    Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EBITDA margin on incremental revenue are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EBITDA margin on incremental revenue include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including other (income) expense, net and interest (income) expense, net; (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, our non-GAAP measures may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate these measures, limiting their usefulness as comparative measures. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EBITDA margin on incremental revenue alongside other financial performance measures, including our net income, gross margin, and our other GAAP results.

    We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; other (income) expense, net; interest income, net; and benefit for income taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We calculate Adjusted EBITDA margin on incremental revenue as incremental Adjusted EBITDA in 2023 divided by incremental revenue in 2023. Please see Annex A: “Reconciliation of GAAP to Non-GAAP Financial Measures” elsewhere in this press release.

    For Further Information, Please Contact:

    Investors:
    James Hart
    investors@progyny.com 

    Media:
    Selena Yang
    media@progyny.com 


    PROGYNY, INC.
    Consolidated Balance Sheets
    (Unaudited)
    (in thousands, except share and per share amounts)

         March 31, December 31,
       2023  2022
          
    ASSETS        
    Current assets:      
    Cash and cash equivalents $        155,320  $        120,078 
    Marketable securities          52,569           69,222 
    Accounts receivable, net of $33,447 and $28,328 of allowances at March 31, 2023 and December 31, 2022, respectively          313,245           240,067 
    Prepaid expenses and other current assets          5,945           4,489 
    Total current assets  527,079   433,856 
    Property and equipment, net  8,883   8,371 
    Operating lease right-of-use assets  18,872   6,903 
    Goodwill  11,880   11,880 
    Intangible assets, net  —   99 
    Deferred tax assets  79,237   77,889 
    Other noncurrent assets  3,773   3,988 
    Total assets $649,724  $542,986 
    LIABILITIES AND STOCKHOLDERS’ EQUITY        
    Current liabilities:        
    Accounts payable $145,623  $109,287 
    Accrued expenses and other current liabilities  61,244   50,249 
    Total current liabilities  206,867   159,536 
    Operating lease noncurrent liabilities  18,456   6,482 
    Total liabilities  225,323   166,018 
    Commitments and Contingencies      
    STOCKHOLDERS' EQUITY      
    Common stock, $0.0001 par value; 1,000,000,000 shares authorized at March 31, 2023 and December 31, 2022; 94,319,215 and 93,301,156 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively  9   9 
    Additional paid-in capital  379,065   349,533 
    Treasury stock, at cost, $0.0001 par value; 615,980 shares at March 31, 2023 and December 31, 2022  (1,009)  (1,009)
    Accumulated earnings  45,612   27,934 
    Accumulated other comprehensive income  724   501 
    Total stockholders’ equity   424,401   376,968 
    Total liabilities and stockholders’ equity  $649,724  $542,986 
     

    PROGYNY, INC.
    Consolidated Statements of Operations
    (Unaudited)
    (in thousands, except share and per share amounts)

     Three Months Ended
    March 31,
     2023 2022
    Revenue$258,394 $172,217 
    Cost of services 199,754  139,268 
    Gross profit 58,640  32,949 
    Operating expenses:   
    Sales and marketing 14,282  10,015 
    General and administrative 29,347  22,992 
    Total operating expenses 43,629  33,007 
    Income (loss) from operations 15,011  (58)
    Other income (expense), net:   
    Other income (expense), net 498  (96)
    Interest income, net 822  12 
    Total other income (expense), net 1,320  (84)
    Income (loss) before income taxes 16,331  (142)
    Benefit for income taxes 1,347  5,113 
    Net income$17,678 $4,971 
    Net income per share:   
    Basic$0.19 $0.05 
    Diluted$0.18 $0.05 
    Weighted-average shares used in computing net income per share:   
    Basic 93,832,873  91,410,368 
    Diluted 100,166,008  99,935,735 
     

    PROGYNY, INC.
    Consolidated Statements of Cash Flows
    (Unaudited)
    (in thousands)

      Three Months Ended
    March 31,
       2023  2022
    OPERATING ACTIVITIES       
    Net income $17,678  $4,971 
    Adjustments to reconcile net income to net cash provided by (used in) operating activities:      
    Deferred tax benefit  (1,347)  (5,155)
    Depreciation and amortization  541   364 
    Stock-based compensation expense  30,808   24,500 
    Bad debt expense  5,244   2,281 
    Realized gains on sale of marketable securities  (502)  — 
    Changes in operating assets and liabilities:      
    Accounts receivable  (78,422)  (65,845)
    Prepaid expenses and other current assets  (1,456)  (664)
    Accounts payable  36,445   23,171 
    Accrued expenses and other current liabilities  11,751   6,489 
    Other noncurrent assets and liabilities  221   (1,374)
    Net cash provided by (used in) operating activities  20,961   (11,262)
           
    INVESTING ACTIVITIES      
    Purchase of property and equipment, net  (1,251)  (790)
    Purchase of marketable securities  (23,435)  (59,867)
    Sale of marketable securities  40,813   21,099 
    Net cash provided by (used in) investing activities  16,127   (39,558)
           
    FINANCING ACTIVITIES      
    Proceeds from exercise of stock options  1,675   830 
    Payment of employee taxes related to equity awards  (3,815)  (2,988)
    Proceeds from contributions to employee stock purchase plan  294   386 
    Net cash used in financing activities  (1,846)  (1,772)
    Net increase (decrease) in cash and cash equivalents  35,242   (52,592)
    Cash and cash equivalents, beginning of period  120,078   91,413 
    Cash and cash equivalents, end of period $155,320  $38,821 
           
    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION      
    Cash paid for income taxes, net of refunds received $(20) $5 
    SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES      
    Additions of property and equipment, net included in accounts payable and accrued expenses $201  $251 
             

    ANNEX A

    PROGYNY, INC.
    Reconciliation of GAAP to Non-GAAP Financial Measures
    (unaudited)
    (in thousands)


    Costs of Services, Gross Margin and Operating Expenses Excluding Stock-Based Compensation Calculation
    The following table provides a reconciliation of cost of services, gross profit, sales and marketing and general and administrative expenses to each of these measures excluding the impact of stock-based compensation expense for each of the periods presented:

      Three Months Ended
      March 31, 2023
         GAAP Stock-Based
    Compensation
    Expense    		 Non-GAAP
           
    Cost of services $199,754  $(8,214) $191,540 
    Gross profit $58,640  $8,214  $66,854 
    Sales and marketing $14,282  $(6,568) $7,714 
    General and administrative $29,347  $(16,026) $13,321 
           
    Expressed as a Percentage of Revenue  
    Gross margin  22.7%  3.2%  25.9%
    Sales and marketing  5.5%  (2.5)%  3.0%
    General and administrative  11.4%  (6.2)%  5.2%
           
      Three Months Ended
      March 31, 2022
         GAAP Stock-Based
    Compensation
    Expense    		 Non-GAAP
           
    Cost of services $139,268  $(6,165) $133,103 
    Gross profit $32,949  $6,165  $39,114 
    Sales and marketing $10,015  $(4,763) $5,252 
    General and administrative $22,992  $(13,572) $9,420 
           
    Expressed as a Percentage of Revenue  
    Gross margin  19.1%  3.6%  22.7%
    Sales and marketing  5.8%  (2.8)%  3.0%
    General and administrative  13.4%  (7.9)%  5.5%
           

    Note: percentages shown in the table may not cross foot due to rounding.

    Adjusted EBITDA and Adjusted EBITDA Margin on Incremental Revenue Calculation
    The following table provides a reconciliation of Net income to Adjusted EBITDA for each of the periods presented:

     Three Months Ended
     March 31,
      2023   2022 
        
    Net income$17,678  $4,971 
    Add:   
    Depreciation and amortization 541   364 
    Stock‑based compensation expense 30,808   24,500 
    Other (income) expense, net (498)  96 
    Interest income, net (822)  (12)
    Benefit for income taxes (1,347)  (5,113)
    Adjusted EBITDA$46,360  $24,806 
        
    Revenue$258,394  $172,217 
        
    Incremental revenue vs. 2022 86,177   
        
    Incremental Adjusted EBITDA vs. 2022 21,554   
        
    Adjusted EBITDA margin on incremental revenue 25.0%  
          

    Reconciliation of Non-GAAP Financial Guidance for the Three Months Ending June 30, 2023 and Year Ending December 31, 2023

     Three Months Ending
    June 30, 2023    		 Year Ending
    December 31, 2023
    (in thousands)Low High Low High
            
    Revenue$260,000  $265,000  $1,040,000  $1,065,000 
    Net Income$9,300  $10,400  $43,600  $49,000 
    Add:       
    Depreciation and amortization 600   600   2,500   2,500 
    Stock-based compensation expense 32,000   32,000   129,000   129,000 
    Other income, net (1,400)  (1,400)  (7,000)  (7,000)
    Provision for income taxes 3,500   3,900   8,400   10,500 
    Adjusted EBITDA*$44,000  $45,500  $176,500  $184,000 

    * All of the numbers in the table above reflect our future outlook as of the date hereof.  Net income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity. 


    Primary Logo

Share on,